Literature DB >> 28906069

Distribution of Amyloid-Like and Oligomeric Species from Protein Aggregation Kinetics.

Alexandra Silva1, Bruno Almeida1,2,3, Joana S Fraga1, Pablo Taboada4, Pedro M Martins1,5,6, Sandra Macedo-Ribeiro1.   

Abstract

Amyloid fibrils and soluble oligomers are two types of protein aggregates associated with neurodegeneration. Classic therapeutic strategies try to prevent the nucleation and spread of amyloid fibrils, whilst diffusible oligomers have emerged as promising drug targets affecting downstream pathogenic processes. We developed a generic protein aggregation model and validate it against measured compositions of fibrillar and non-fibrillar assemblies of ataxin-3, a protein implicated in Machado-Joseph disease. The derived analytic rate-law equations can be used to 1) identify the presence of parallel aggregation pathways and 2) estimate the critical sizes of amyloid fibrils. The discretized population balance supporting our model is the first to quantitatively fit time-resolved measurements of size and composition of both amyloid-like and oligomeric species. The new theoretical framework can be used to screen a new class of drugs specifically targeting toxic oligomers.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  amyloid; kinetics; protein aggregation; self-assembly; soluble oligomers

Mesh:

Substances:

Year:  2017        PMID: 28906069     DOI: 10.1002/anie.201707345

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  7 in total

Review 1.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

2.  A Robust Assay to Monitor Ataxin-3 Amyloid Fibril Assembly.

Authors:  Francisco Figueiredo; Mónica Lopes-Marques; Bruno Almeida; Nena Matscheko; Pedro M Martins; Alexandra Silva; Sandra Macedo-Ribeiro
Journal:  Cells       Date:  2022-06-19       Impact factor: 7.666

3.  Inhibition of Lysozyme Amyloid Fibrillation by Silybin Diastereoisomers: The Effects of Stereochemistry.

Authors:  Xuanyu Chen; Xiaomin Deng; Xingxing Han; Yinmei Liang; Zhiping Meng; Rui Liu; Wenqiang Su; Huaxu Zhu; Tingming Fu
Journal:  ACS Omega       Date:  2021-01-20

Review 4.  MIRRAGGE - Minimum Information Required for Reproducible AGGregation Experiments.

Authors:  Pedro M Martins; Susanna Navarro; Alexandra Silva; Maria F Pinto; Zsuzsa Sárkány; Francisco Figueiredo; Pedro José Barbosa Pereira; Francisca Pinheiro; Zuzana Bednarikova; Michał Burdukiewicz; Oxana V Galzitskaya; Zuzana Gazova; Cláudio M Gomes; Annalisa Pastore; Louise C Serpell; Rostislav Skrabana; Vytautas Smirnovas; Mantas Ziaunys; Daniel E Otzen; Salvador Ventura; Sandra Macedo-Ribeiro
Journal:  Front Mol Neurosci       Date:  2020-11-27       Impact factor: 5.639

5.  Aggregation Time Machine: A Platform for the Prediction and Optimization of Long-Term Antibody Stability Using Short-Term Kinetic Analysis.

Authors:  Marko Bunc; San Hadži; Christian Graf; Matjaž Bončina; Jurij Lah
Journal:  J Med Chem       Date:  2022-01-28       Impact factor: 7.446

6.  Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws.

Authors:  Alexandra Silva; Zsuzsa Sárkány; Joana S Fraga; Pablo Taboada; Sandra Macedo-Ribeiro; Pedro M Martins
Journal:  Biomolecules       Date:  2018-10-04

7.  Fluorescence Lifetime and Intensity of Thioflavin T as Reporters of Different Fibrillation Stages: Insights Obtained from Fluorescence Up-Conversion and Particle Size Distribution Measurements.

Authors:  Nataliya R Rovnyagina; Gleb S Budylin; Yuri G Vainer; Tatiana N Tikhonova; Sergey L Vasin; Alexander A Yakovlev; Victor O Kompanets; Sergey V Chekalin; Alexander V Priezzhev; Evgeny A Shirshin
Journal:  Int J Mol Sci       Date:  2020-08-26       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.